All In Biotech

Free tool

FAERS Monitor: Orabloc

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 022466 or its brand name (Orabloc, Articaine Hydrochloride, Epinephrine Bitartrate). Reports on generic versions are filed under their own applications.

Reports

180

Serious

76

42% of reports

Hospitalization

21

Death reported

2

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • drug ineffective56
  • dizziness10
  • loss of consciousness9
  • hypoaesthesia oral8
  • paraesthesia8
  • therapeutic product effect prolonged8
  • anaphylactic shock7
  • drug effect prolonged7
  • nausea6
  • pain6
  • drug effect incomplete5
  • hypoaesthesia5
  • malaise5
  • palpitations5
  • urticaria5

Reports by year received

View as table
YearReports
20102
20111
20123
20144
20155
20169
201725
20187
201915
202016
202110
202210
202326
202424
202517
20266

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,979 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
therapeutic product effect prolongedSignal82102.81061.314,510
drug effect prolongedSignal71502.3723.28,940
hypoaesthesia oralSignal862.131.5422
anaphylactic shockSignal731.715.4179
drug effect incompleteSignal516.16.857
loss of consciousnessSignal98.24.350
paraesthesiaSignal85.93.028
palpitationsSignal55.02.112
drug ineffectiveSignal565.04.0185
hypoaesthesiaSignal53.91.68
urticariaSignal53.51.57
dizzinessSignal102.31.37
malaise51.30.60
pain61.10.50
nausea60.90.40

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.